Study identification

EU PAS number

EUPAS104768

Study ID

104769

Official title and acronym

Cross-sectional Study Evaluating the Effectiveness of the Venetoclax Patient Card Among Adult Patients in Europe

DARWIN EU® study

No

Study countries

France
Germany
Poland
Spain
United Kingdom

Study description

This study will be a cross-sectional survey of knowledge of the risks and safe use of venetoclax as outlined in the patient card among adult patients who have recently received venetoclax for treatment of CLL per standard of care. Patients will be identified through a diverse selection of medical practices representing haematologists who prescribe venetoclax across at least 5 European countries. Patients will be invited to participate by their physician and will be asked to complete a one-time self-administered structured questionnaire.

Study status

Ongoing
Research institutions and networks

Institutions

RTI Health Solutions (RTI-HS)
France
Spain
Sweden
United Kingdom
United Kingdom (Northern Ireland)
United States
First published:
13/03/2025
Institution Not-for-profit ENCePP partner

Contact details

Daniel Wolin

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AbbVie
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)